Paragon 28, Inc.
http://www.paragon28.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Paragon 28, Inc.
Going Early For Maximum Long Term Value From Medtech Deals
Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.
Asia Deal Watch: CJ Group Continues Spree With Majority Stake Acquisition In Batavia Biosciences
Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.
Ischemic Stroke: Prying Open the Treatment Window
At this year's International Stroke Conference in San Antonio, some exciting device-based therapies and approaches were discusssed--including advanced imaging, multimodal therapy and stent-like thrombectomy devices--that may offer improved outcomes for patients that suffer an acute ischemic stroke.
Invatec: Translating Global Success in Vascular Devices to the US Market
Invatec has grown to be the leading native European interventional vascular device company and has now set its sights on the US market. By focusing first on peripherals and following with drug-eluting balloons, not stents, Invatec is looking to compete against the major device companies on their home turf.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Biomaterials
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice